Rating Change
Piper Sandler reiterated its Overweight rating on Moderna, Inc. (NASDAQ:MRNA) on October 26, 2026.
reiterateNASDAQ:MRNA
Piper Sandler Reiterates Overweight Rating on Moderna, Inc. (MRNA)
Piper Sandler reiterated its Overweight rating on Moderna, Inc. (NASDAQ:MRNA) on October 26, 2026.
At publication ·
What changed
Moderna, Inc. (NASDAQ:MRNA) · reiterate
- Firm
- Piper Sandler
- Rating
- Overweight to Overweight
- Price at event
- $198.79
- Market capitalization
- $11.6B
At a glance
Key takeaways
- Piper Sandler reiterated an Overweight rating on Moderna on October 26, 2026, while the stock trades at $198.79 with an $11.6B market cap.
- Moderna stock has gained 548.4% over the past 52 weeks, significantly outperforming broader market trends.
- Among the 10 most recent analyst ratings, opinions are mixed: 2 Buy, 5 Hold, and 3 Sell recommendations.
- Recent analyst activity shows diverging views, with Piper Sandler Overweight contrasting against Citigroup Sell and Morgan Stanley Equal-Weight ratings.
Market Context
Moderna, Inc. operates in the Healthcare sector. The stock currently trades at $198.79 with a market capitalization of $11.6B. The stock has gained 548.4% over the past 52 weeks.
Analyst coverage from Piper Sandler provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Moderna, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Moderna, Inc.
Among the 10 most recent ratings: 2 Buy, 5 Hold, 3 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 26, 2026 | Piper Sandler | Overweight | N/A |
| Oct 21, 2026 | TD Cowen | Hold | N/A |
| Oct 15, 2026 | Goldman Sachs | Neutral | N/A |
| Oct 07, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Sep 30, 2026 | Citigroup | Sell | N/A |
Related Tools: Analyst Ratings Dashboard | View MRNA Stock Page
Frequently Asked Questions
What does the Overweight rating mean for MRNA?
A rating of Overweight from Piper Sandler reflects the analyst's outlook on Moderna, Inc. (NASDAQ:MRNA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRNA forecast page.
Loading related coverage…
